Page last updated: 2024-11-12

alemcinal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9918079
CHEMBL ID300049
MeSH IDM0294765

Synonyms (24)

Synonym
abt229
gtpl1444
(1r,2r,3s,4s,5r,8r,9r,10s,11r)-8-ethyl-2-[(2s,3r,4s,6r)-4-(ethyl-methylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-hydroxy-4-[(2s,4s,6s)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-1,3,5,9,11,13-hexamethyl-7,15-dioxabicyclo[10.2.1]pentadec-12-en-6-one
D02801
150785-53-8
alemcinal (usan/inn)
alemcinal
alemcinal [usan:inn]
8,9-didehydro-n-demethyl-9-deoxo-4',6,12-trideoxy-6,9-epoxy-n-ethylerythromycin
CHEMBL300049
abbott-81229.0
abt-229
a-81229
5ds173odi4 ,
unii-5ds173odi4
abt 229
8,9-didehydro-n-demethyl-9-deoxo-4', 6, 12-trideoxy-6,9-epoxy-n-ethylerythromycin
bdbm86685
8,9-didehydro-n-demethyl-9-deoxo-4'',6,12-trideoxy-6,9-epoxy-n-ethylerythromycin
alemcinal [usan]
alemcinal [inn]
Q27074378
(2r,3s,4r,5r,8r,9s,10s,11r,12r)-5-ethyl-11-[(2s,3r,4s,6r)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3-hydroxy-9-[(2s,4s,6s)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
AKOS040750313

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" ABT-229 was > 300,000 times more potent than erythromycin in vitro and had 39% oral bioavailability in dog compared to its 4",12-dihydroxy congener (EM-523), which was only 400 times more potent than erythromycin and had relatively low (1."( Synthesis of 4"-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.
Edwards, CM; Faghih, R; Freiberg, L; Klein, LL; Lartey, PA; Marsh, K; Nellans, HN; Petersen, A; Plattner, JJ; Quigley, S, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" A randomized, double-blind, placebo-controlled, three-period incomplete crossover design was used with three dosing periods of 7 days."( The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients.
Samsom, M; Smout, AJ; Van Herwaarden, MA; Van Nispen, CH; Verlinden, M, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID25648Half life period after oral administration in the dog1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis of 4"-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.
AID234709Activity relative to erythromycin A1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis of 4"-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.
AID167005In vitro smooth muscle contractility using isolated rabbit duodenum1998Bioorganic & medicinal chemistry letters, Apr-07, Volume: 8, Issue:7
Preparation of 9-deoxo-4"-deoxy-6,9-epoxyerythromycin lactams "motilactides": potent and orally active prokinetic agents.
AID16045Oral bioavailability in dog1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis of 4"-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.
AID167709The compound was tested in vitro for prokinetic activity as smooth muscle contractility in isolated rabbit duodenum1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis of 4"-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.
AID1346284Human motilin receptor (Motilin receptor)2005The Journal of pharmacology and experimental therapeutics, Jun, Volume: 313, Issue:3
Desensitization of the human motilin receptor by motilides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (30.00)18.2507
2000's11 (55.00)29.6817
2010's3 (15.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.96 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (30.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (65.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]